In order to realize the ambition of RegMed XB to bring solutions to the patients on a large scale the RM products we develop will have to be commercialized. This will ensure large-scale production and efficient production methods to reduce costs. Furthermore, the expertise in the RegMed XB ecosystem can also boost the development of new and existing products from the emerging RM companies. All in all, it is a perfect match to partner up with companies to access their expertise to design scalable and feasible products and together scout for opportunities to valorize new opportunities in the pipeline of the companies or the academic partners. Currently, we have strong partnerships with the following entities.
Access2Bone is a start-up in the orthopaedic market of bone void fillers. Worldwide the number of bone grafting procedures performed in an ever more geriatric population is growing rapidly. For a growing group of geriatric patients with a compromised bone regeneration metabolism Access2Bone is to create the best bone void filling solutions surgeons need to help these patients best. Access2Bone envisions to lead the high-end segment of bone void fillers by creating highly osteo inductive products that are safe by design and disruptively efficient. Access2Bone’s products are based on naturally derived growth factors. Access2Bone is aiding the Osteoarthritis Moonshot with coating implants that being developed by the Moonshot team with A2B’s growth factors to stimulate fusion between the patient’s bone and the implants being developed.
Osteo--Pharma is a Life Sciences company that focuses on bone regeneration and is developing innovative medical devices and pharmaceuticals for the orthopedic and dental field. Osteo-Pharma applies its patented, OsteoActivator® technology that enables sustained delivery over multiple weeks of ancillary amounts of bone healing compounds for local treatment of a bone fracture or bone defect. The European Patent Office has recently granted a composition of matter patent covering OsteoActivator® formulations. The Osteo-Pharma portfolio consists of:
Osteo-pharma has successfully completed pre-clinal studies and is now actively advancing its lead products towards the clinic and market.
A clinical-stage medical device company, Xeltis developed the world’s first polymer-based technology platform to enable natural restoration of heart valves and blood vessels within the body.
The technology uses the patient’s own natural healing system to develop a new living functional vascular graft or heart valve. Xeltis devices are made of supramolecular polymers (a Nobel prize awarded discovery). They are manufactured with electrospinning methods to create small diameter vascular grafts and heart valve implants with a unique micro-porous architecture.